Add on Lacosamide Versus High Dose Monotherapy
Open Label Trial of Add on Lacosamide Versus High Dose Monotherapy in Patients With a Seizure Disorder
Sponsor: Brigham and Women's Hospital
Listed as NCT01345058, this observational or N/A phase trial focuses on Epilepsy and remains completed. Sponsored by Brigham and Women's Hospital, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Apr 16, 2026 — Present [daily]
Completed
Phase: PHASE3 → None
-
Sep 2024 — Apr 2026 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2017 — Jun 2017 [monthly]
Unknown Status PHASE3
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a study to determine whether a combination of low dose lacosamide and levetiracetam is more effective than high dose levetiracetam in patients who have failed low dose levetiracetam.
Contact Information
- Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .